Millennium Pharmaceuticals, Inc. has initiated a randomized, multicenter, company-sponsored phase III trial to determine the most effective Velcade (bortezomib)-based combination therapy with approved agents for the treatment of newly diagnosed multiple myeloma patients who are ineligible for stem cell transplantation
CAMBRIDGE, MassachusettsMillennium Pharmaceuticals, Inc. has initiated a randomized, multicenter, company-sponsored phase III trial to determine the most effective Velcade (bortezomib)-based combination therapy with approved agents for the treatment of newly diagnosed multiple myeloma patients who are ineligible for stem cell transplantation.
The trial, named UPFRONT and conducted primarily at community physician networks nationwide, will compare three Velcade-based therapies. Principal investigator is Ruben Niesvizky, MD, associate professor of medicine, New York-Presbyterian Hospital/Weill Cornell Medical Center. Velcade is currently approved for myeloma patients who have received at least one prior therapy.
UPFRONT will evaluate the safety and efficacy of Velcade and dexamethasone (VD); Velcade, thalidomide (Thalomid), and dexamethasone (VTD); and Velcade, melphalan, and prednisone (VMP). The primary endpoint is progression-free survival, with secondary endpoints including duration of response, overall survival, and overall safety/tolerability. Target enrollment is up to 500 patients, who will be treated for up to 1 year.
UPFRONT has a unique adaptive design, providing the flexibility to modify the therapies (following an interim analysis) should a new standard of care be established. The adaptive design will help ensure that the most effective treatment options are evaluated in the most efficient way, the company said.
For more information, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-835-2233 (1-866-VELCADE). Additional information can also be found at www.velcade.com.
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.